# Complete radiologic and clinical reversal of lumbar spinal epidural lipomatosis via GLP-1 agonist.

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/spinal-epidural-lipomatosis-glp1-agonist-treatment-reversal/
> **Published:** 2026-04-28T02:03:23-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:00:13-04:00
> **Clinical Summary:** Case report shows complete spinal epidural lipomatosis reversal with GLP-1 agonist weight loss and medical cannabis, avoiding surgery in morbid obesity.

---

CED Clinical Relevance  #64Notable Clinical Interest
Evidence Brief | CED ClinicCase report demonstrates complete reversal of spinal epidural lipomatosis through GLP-1 agonist weight loss combined with medical [cannabis pain management](https://cedclinic.com/age-dependent-effects-tetrahydrocannabinol-pain-relief/).
Spinal StenosisWeight LossGlp-1 Agonists[Medical Cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/)Case Report

Case report demonstrates complete reversal of spinal epidural lipomatosis through GLP-1 agonist weight loss combined with [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) [pain management](https://cedclinic.com/cbd-cbg-topicals-for-eczema/).

What This Study Teaches Us

This case demonstrates that obesity-related spinal epidural lipomatosis can be reversible through sustained weight loss. The combination of GLP-1 agonist therapy with medical cannabis provided both weight reduction and pain control without requiring surgical intervention.

Why This Matters
Spinal epidural lipomatosis typically requires surgical decompression when severe, carrying operative risks. This case suggests that medical management targeting underlying obesity may offer an alternative approach, particularly relevant given the expanding availability of GLP-1 agonists.

Study Snapshot

Study Type
Case Report

Population
Single 48-year-old man with morbid obesity (153 kg) and spinal epidural lipomatosis

Intervention
GLP-1 agonist (semaglutide) for weight loss plus medical [cannabis for pain](https://cedclinic.com/cannabis-veterans-substance-use-disorder-study/) control

Comparator
None (case report)

Primary Outcome
Radiologic resolution of epidural lipomatosis and clinical improvement

Key Finding
Weight reduction from 153 kg to 93.8 kg over one year with near-complete MRI regression of epidural fat and resolution of stenosis

Journal
Journal of Surgical Case Reports

Year
2024

Clinical Bottom Line
In selected patients with obesity-related spinal epidural lipomatosis, sustained weight loss through GLP-1 agonist therapy may achieve radiologic and clinical resolution. Medical cannabis appeared to provide effective adjunctive [pain management](https://cedclinic.com/cbd-cbg-topicals-for-eczema/) during the weight loss period.

What This Paper Does Not Show
This single case report cannot establish efficacy, safety, or reproducibility of this approach. It provides no data on optimal timing, patient selection criteria, or comparative effectiveness versus surgical intervention.

Where This Paper Deserves Skepticism
Case reports represent the lowest level of evidence and are subject to selection bias. The dramatic weight loss achieved may not be reproducible in all patients, and the specific contribution of cannabis versus weight loss alone to pain improvement cannot be determined.

Dr. Caplan's Take
This case is intriguing but represents anecdotal evidence that shouldn’t change standard practice yet. I’d be cautious about delaying appropriate surgical intervention based on a single case, though the combination of GLP-1 therapy with cannabis for bridging pain control seems clinically sensible in appropriate candidates.

What a Careful Reader Should Take Away

While encouraging, this single case report requires validation through larger studies before influencing clinical guidelines. The principle of addressing underlying obesity in spinal epidural lipomatosis appears sound, but patient selection and timing relative to surgical options remain undefined.

Join the Conversation

Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan)

Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/)

Have thoughts on this? Share it:

[X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Complete%20radiologic%20and%20clinical%20reversal%20of%20lumbar%20spinal%20epidural%20lipomatosis%20via%20GLP-1%20agonist.%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2Fspinal-epidural-lipomatosis-glp1-agonist-treatment-reversal%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fspinal-epidural-lipomatosis-glp1-agonist-treatment-reversal%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Complete%20radiologic%20and%20clinical%20reversal%20of%20lumbar%20spinal%20epidural%20lipomatosis%20via%20GLP-1%20agonist.%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2Fspinal-epidural-lipomatosis-glp1-agonist-treatment-reversal%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/)

Table of Contents

- [FAQ](#FAQ)[What is spinal epidural lipomatosis and when should non-surgical treatment be considered?](#What_is_spinal_epidural_lipomatosis_and_when_should_non-surgical_treatment_be_considered)
- [How effective are GLP-1 agonists like semaglutide for treating obesity-related spinal conditions?](#How_effective_are_GLP-1_agonists_like_semaglutide_for_treating_obesity-related_spinal_conditions)
- [What role does medical cannabis play in managing spinal stenosis pain?](#What_role_does_medical_cannabis_play_in_managing_spinal_stenosis_pain)
- [Can spinal epidural lipomatosis be completely reversed without surgery?](#Can_spinal_epidural_lipomatosis_be_completely_reversed_without_surgery)
- [What monitoring is needed when using this combined treatment approach?](#What_monitoring_is_needed_when_using_this_combined_treatment_approach)
- [Related](#Related)

## FAQ

#### What is spinal epidural lipomatosis and when should non-surgical treatment be considered?

Spinal epidural lipomatosis (SEL) is a rare condition where excess fat accumulates in the spinal canal, causing stenosis and neurologic symptoms, typically associated with obesity or steroid use. This case demonstrates that medical weight loss with GLP-1 agonists can achieve complete reversal, suggesting non-surgical approaches should be considered in obesity-related SEL before proceeding to decompression surgery.

#### How effective are GLP-1 agonists like semaglutide for treating obesity-related spinal conditions?

This case shows remarkable efficacy, with semaglutide facilitating 59.2 kg weight loss (from 153 kg to 93.8 kg) over one year, resulting in near-complete regression of epidural fat and resolution of spinal stenosis. The dramatic radiologic and clinical improvement suggests GLP-1 agonists may be highly effective for obesity-related spinal disorders when significant weight loss is achieved.

#### What role does medical cannabis play in managing spinal stenosis pain?

In this case, medical cannabis was successfully used as part of a non-opioid pain management strategy during the weight loss treatment period. Cannabis provided adequate pain control while avoiding opioid dependence risks, supporting its utility as an adjunctive therapy in comprehensive spinal stenosis management.

#### Can spinal epidural lipomatosis be completely reversed without surgery?

Yes, this appears to be the first documented case of complete SEL reversal through medical weight loss alone. MRI demonstrated near-complete regression of epidural fat and resolution of stenosis, with the patient maintaining neurologic integrity and experiencing major improvements in pain and mobility.

#### What monitoring is needed when using this combined treatment approach?

Patients require regular monitoring of weight loss progress, neurologic status, and pain levels throughout treatment. Serial MRI imaging should be considered to document anatomical improvement and ensure adequate decompression, while monitoring for any GLP-1 agonist [side effects](https://cedclinic.com/cannabis-intoxication-memory-disruption/) and cannabis treatment response.

 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 

Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.

Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance

 [Leave a Message](https://cedclinic.com/contact/)
 [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
 [Medical Consulting](https://cedclinic.com/book/)
 [Cannabis Care](https://cedclinic.com/book/)
 

 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).
